The impact of KRAS mutations on VEGF-A production and tumour vascular network

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Figueras, Agnès ^a   Arbos, Maria Antonia ^b   Quiles, Maria Teresa ^b   Viñals, Francesc ^a,c   Germà, Josep Ramón ^a   Capellà, Gabriel ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

HIF 1 ; KRAS mutations; Tumour angiogenesis; Vascular endothelial growth factor A; VEGF A promoter

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CODON; CONTROLLED STUDY; ENZYME ACTIVATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVESSEL DENSITY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE K RAS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CODON; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; PROMOTER REGIONS, GENETIC; RAS PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875014194     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-125     Document Type: Article

References (40)

1. Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003, 5:5-18.
2. Finkelstein SD. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993, 128:526-531. discussion 531-2, 10.1001/archsurg.1993.01420170056008, 8489386.
3. Finkelstein SD. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993, 71:3827-3838. 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N, 8508351.
4. Guerrero S. Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 2002, 16:1642-1644.
5. Fasano O. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci USA 1984, 81:4008-4012. 10.1073/pnas.81.13.4008, 345357, 6330729.
6. Sloan SR, Newcomb EW, Pellicer A. Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation. Mol Cell Biol 1990, 10:405-408. 360767, 2403644.
7. Zhou W. Hif1alpha induced switch from bivalent to exclusively glycolitic metabolism during ESC-to-EpiSC/hESC transition. EMBO 2012, 31:13.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364. 10.1016/S0092-8674(00)80108-7, 8756718.
9. Carmeliet P. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473.
10. Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000, 19:93-96. 10.1023/A:1026516920119, 11191070.
11. Kalas W, Klement P, Rak J. Downregulation of the angiogenesis inhibitor thrombospondin 1 in fibroblasts exposed to platelets and their related phospholipids. Biochem Biophys Res Commun 2005, 334(2):549-554. 10.1016/j.bbrc.2005.06.123, 16009346.
12. Kranenburg O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004, 1654:23-37.
13. Larcher F. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis. Mol Carcinog 2003, 37(2):83-90. 10.1002/mc.10126, 12766907.
14. Audero E. Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells. J Biol Chem 2004, 279:13224-13233.
15. Guerrero S. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000, 60:6750-6756.
16. Jensen MM. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18 F-FDG-microPET or external caliper. BMC Med Imaging 2008, 8:16. 10.1186/1471-2342-8-16, 2575188, 18925932.
17. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45. 10.1093/nar/29.9.e45, 55695, 11328886.
18. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 2005, 65:564-573. 10.1016/j.cardiores.2004.09.032, 15664382.
19. Grosfeld A. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002, 277(45):42953-42957. 10.1074/jbc.M206775200, 12215445.
20. McKenzie FR, Pouyssegur J. cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition. cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases. J Biol Chem 1996, 271(23):13476-13483. 10.1074/jbc.271.23.13476, 8662790.
21. Berra E. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003, 22(16):4082-4090. 10.1093/emboj/cdg392, 175782, 12912907.
22. Weidner N. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324(1):1-8. 10.1056/NEJM199101033240101, 1701519.
23. Li J. Down-regulation of N-acetylglucosaminyltransferase-V induces ER stress by changing glycosylation and function of GLUT1. Arch Biochem Biophys 2007, 463(1):102-109. 10.1016/j.abb.2007.03.005, 17451637.
24. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009, 29(10):2483-2488. 10.1128/MCB.01828-08, 2682032, 19273606.
25. Vizan P. K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. Cancer Res 2005, 65:5512-5515. 10.1158/0008-5472.CAN-05-0074, 15994921.
26. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001, 61(16):6050-6054.
27. Bradbury D. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005, 280(34):29993-30000. 10.1074/jbc.M414530200, 15970595.
28. Curry JM. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 2008, 3(10):e3405. 10.1371/journal.pone.0003405, 2566603, 18852899.
29. Song Y. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009, 15(2):492-501. 10.1158/1078-0432.CCR-08-1945, 19147754.
30. Pore N. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004, 15(11):4841-4853. 10.1091/mbc.E04-05-0374, 524732, 15342781.
31. Hatzaki A. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes 2001, 15(5):243-247. 10.1006/mcpr.2001.0367, 11735295.
32. Nakatsu MN. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 2003, 83:1873-1885. 10.1097/01.LAB.0000107160.81875.33, 14691306.
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257. 10.1038/35025220, 11001068.
34. Grunstein J. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999, 59:1592-1598.
35. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
36. Greenberg JI. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456(7223):809-813. 10.1038/nature07424, 2605188, 18997771.
37. Paez-Ribes M. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
38. De Roock W. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
39. Diaz-Rubio E. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One 2012, 7(10):e47345. 10.1371/journal.pone.0047345, 3470549, 23174912.
40. Modest DP. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. Anticancer Drugs 2012, 23(6):666-673. 10.1097/CAD.0b013e328352ff1d, 22441566.